Clinical trials: Everyday Activities
Solid Tumor
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
This is a phase 1 study in which 2 to 72 patients with advanced cancer will receive oral doses of rigosertib, a new investigational (unapproved) anti-cancer drug.
- Trial name
- NCT01168011
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Traws Pharma, Inc.
Sjögren-Larsson Syndrome
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered…
- Trial name
- NCT02402309
- Testing
- Active topical NS2 1% dermatologic cream
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Prostatic Cancer, Castration-Resistant
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- DaroAcT (NCT04157088)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Multiple Sclerosis
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple…
- Trial name
- NCT00928967
- Testing
- Interferon beta-1b, (Betaseron BAY86-5046)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Bayer
Down Syndrome
A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.
The purpose of this double-blind, placebo-controlled, comparative study and open-label extension study is to confirm the efficacy and safety of E2020 in subjects with Down syndrome having regression symptoms and disabled…
- Trial name
- NCT02094053
- Testing
- E2020-Donepezil hydrochloride
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eisai Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease
This study was designed to look at effects of salmeterol/fluticasone propionate compared to placebo on airway inflammation in patients with chronic obstructive airways disease
- Trial name
- NCT00268177
- Testing
- Salmeterol/fluticasone propionate 50/500mcg Diskus
- Where
- 20 sites in Denmark, Estonia and 6 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Open Angle Glaucoma -Ocular Hypertension
28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
Primary Objective: To assess the local and systemic safety and tolerability of ascending repeated topical doses of SAR366234 monotherapy in patients with open angle glaucoma (OAG) or ocular hypertension (OHT) as compared to…
- Trial name
- NCT02531152
- Testing
- Latanoprost, SAR366234
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
Primary Biliary Cholangitis (PBC)
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
The purpose of this study is to understand how tiredness changes in adults with Primary Biliary Cholangitis (PBC) after starting elafibranor in routine clinical practice.
- Trial name
- NCT07906639
- Testing
- Elafibranor
- Volunteers
- 50 people
- Sponsor
- Ipsen
Dementia, Alzheimer Disease
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.
- Conditions
- Dementia, Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- NCT05418296
- Testing
- A novel digital health device
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- mandy
Chronic Obstructive Pulmonary Disease
Cross-sectional Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities
The purpose of this study is to investigate the effects of Chronic Obstructive Pulmonary Disease (COPD) on daily life activities in patients with COPD and also to determine the socio-demographic profile, daily life style and…
- Trial name
- COPD LIFE (NCT01325948)
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 497 people
- Sponsor
- AstraZeneca
Quality of Life, Epilepsy (treatment Refractory)
Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data
The study will be prospective, multicentre, postmarketing clinical study, with a controlled and randomized design, to perform the analysis of 130 subjects with a clinical diagnosis of epilepsy, patients whose clinical semiology…
- Trial name
- SERAS_Home_RWD (NCT05845255)
- Testing
- mjn-SERAS
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 130 people
- Sponsor
- MJN Neuroserveis, S.L
Myopia, Myopia Progression
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing standard single vision spectacle lenses and myopia control spectacle lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- NCT07229352
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Sleep Apnea, Obstructive, Obstructive Sleep Apnea Syndrome
Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk
The aim of this study is to determine the usefulness of a telemedicine system for the follow-up of OSA patients with a high cardiovascular risk.
- Trial name
- TELESAS (NCT01226641)
- Testing
- Telemedicine, Standard care
- Where
- 14 sites in France
- Volunteers
- 107 people
- Sponsor
- Initiative Pour la Sante
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in…
- Trial name
- NCT07266831
- Testing
- ISL, ULO, BIC/FTC/TAF
- Where
- 56 sites in United States, Argentina and 7 more
- Volunteers
- 570 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise
The primary objective of this study is to demonstrate that the combination of inhaled fluticasone furoate/vilanterol (100 mcg/25 mcg) once daily provides superior protection throughout the day against bronchoconstriction induced…
- Trial name
- NCT01435902
- Testing
- Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Propionate Inhalation Powder
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
The primary objective of the study is to investigate the effect of the combined therapy 18 μg tiotropium q.d. plus pulmonary rehabilitation versus placebo plus pulmonary rehabilitation on 6-minute walking distance (6MWD) after 7…
- Trial name
- NCT02172508
- Testing
- Tiotropium Inhalation Capsule
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Myelodysplastic Syndrome
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
In other clinical studies, ON 01910.Na has been safely given intravenously to Patients with advanced cancers. However, to treat some Patients, it may be better if ON 01910.Na could be given by mouth.
- Trial name
- NCT01048619
- Testing
- ON 01910.Na
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.
HIV Infections
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo- controlled, functional monotherapy phase to quantify the antiviral activity attributable to dolutegravir (DTG) in HIV-1 infected, ART-experienced…
- Trial name
- VIKING-4 (NCT01568892)
- Testing
- Dolutegravir 50 mg twice daily
- Where
- 25 sites in United States
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
HIV Infections
TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains
The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a current treatment regimen that…
- Trial name
- NCT00964327
- Testing
- TMC114
- Volunteers
- 42 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland